Fig. 4 | Scientific Reports

Fig. 4

From: Baseline selenium is associated with response to intravenous Methylprednisolone with selenium supplementation for thyroid eye disease in a selenium-sufficient area

Fig. 4

Comparison of the Clinical Activity Score (CAS) improvement and baseline-adjusted final CAS according to baseline selenium (Se) level. (A) Boxplot showing the change in CAS (ΔCAS) in patients with a baseline Se level of < 147.53 µg/L (n = 31) and ≥ 147.53 µg/L (n = 11). The box indicates the interquartile range (IQR), the horizontal line represents the median, and the whiskers represent 1.5×IQR. Patients with a Se level of ≥ 147.53 µg/L showed a significantly greater reduction in CAS than did those with lower levels (p = 0.012, Mann–Whitney U test). The median ΔCAS was − 2.0 in the high-Se group and − 1.0 in the low-Se group. (B) Estimated marginal means (EMMs) of final CAS (FU3) ± 95% CIs for each Se group derived from a linear analysis of covariance (ANCOVA) adjusting for baseline CAS. EMMs are displayed at baseline CAS = 3 (EMM high-Se group 1.09 vs. low-Se 2.06). In both the full cohort (n = 42) and the active-only subset (baseline CAS ≥ 3; n = 27), the high‑Se group had lower adjusted final CAS; p = 0.017 and p = 0.045, respectively (rank-based ANCOVA). FU0, baseline; FU3, 2 months after treatment completion.

Back to article page